Our R&D portfolio for cryptococcal meningitis
What we have achieved
We have joined a broad network of partner organizations, the Cryptococcal Meningitis Action Group, advocating for better access to life-saving treatment combinations for people with cryptococcal meningitis. Ending cryptococcal meningitis deaths by 2030 is its overarching goal.
What we are doing for people living with cryptococcal meningitis
Our aim is to facilitate the scale-up of key medicines in selected, trailblazer African low- and middle-income countries through a comprehensive action plan. We are also working to develop a better formulation of the existing medicines.
Building capacity, uniting expertise
Initiatives to utilize and strengthen research capacities in low- and middle-income countries and support networks of excellence to sustain public-interest R&D are central to our virtual R&D model.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in more than 40 countries.
Get our latest news, personal stories, research articles, and job opportunities.